Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boyd C Clarke Insider Profile
4 Followers
Boyd C Clarke, Director at Aldeyra Therapeutics, holds 15.50K shares in Aldeyra Therapeutics (Ticker: ALDX). Most recently, Boyd C Clarke Bought $3,000 shares of Aldeyra Therapeutics on Aug 07, 2014 for an estimated value of 11.04K.
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+61.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Boyd C Clarke holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 07, 2014 - Aug 07, 2015
Return:+115.50%
The most profitable trade made by Boyd C Clarke
Boyd C Clarke's Trading History
List of latest transactions for each holding click on a transaction to see Boyd C Clarke's performance on stock
You May Also Like
Boyd C Clarke insider profile FAQ
What is the percentage of profitable transactions made by Boyd C Clarke?
The percentage of profitable transactions made by Boyd C Clarke is 100%.
What is the average return per transaction made by Boyd C Clarke?
The average return per transaction made by Boyd C Clarke is 61.70%.
What stocks does Boyd C Clarke hold?
Boyd C Clarke holds: ALDX stocks.
What was Boyd C Clarke’s latest transaction?
Boyd C Clarke latest transaction was an Informative Buy of $11.04K.
What was Boyd C Clarke's most profitable transaction?
Boyd C Clarke’s most profitable transaction was an Informative Buy of ALDX stock on August 7, 2014. The return on the trade was 115.50%.
What is Boyd C Clarke's role in Aldeyra Therapeutics?
Boyd C Clarke's role in Aldeyra Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.